Need to test the arterial inflammation hypothesis

Circulation

Volumn 106, Issue 1, 2002, Pages 136-140

  Bhatt, Deepak L ^a   Topol, Eric J ^a  

^a NONE   (United States)

Author keywords

Arteries; Coronary disease; Inflammation

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; ISCHEMIA; MODELS, CARDIOVASCULAR; MYOCARDIAL REVASCULARIZATION; RISK FACTORS;

EID: 0036645047     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000021112.29409.A2     Document Type: Review

References (79)

1. C-reactive protein: Linking inflammation to cardiovascular complications
2. A tale of two diseases: Atherosclerosis and rheumatoid arthritis
3. Atherosclerosis: An inflammatory disease
4. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
5. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention
6. Direct proinflammatory effect of C-reactive protein on human endothelial cells
7. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
8. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
9. Generation of C-Reactive protein and complement components in atherosclerotic plaques
10. Unstable angina and elevated C-reactive protein levels predict enhanced vasoreactivity of the culprit lesion
11. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
12. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
13. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects
14. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris
15. Inflammatory markers in coronary artery disease: Let prevention douse the flames
16. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
17. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction
18. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. CAPTURE Investigators. Chimeric c7E3 anti-platelet therapy in unstable angina refractory to standard treatment trial
19. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in myocardial infarction
20. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease
21. C-reactive protein concentrations and angiographic characteristics of coronary lesions
22. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
23. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina
24. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
25. C-reactive protein and the stress test for risk stratification of patients recovering from unstable angina pectoris
26. C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina
27. C-reactive protein in ischemic stroke: An independent prognostic factor
28. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
29. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
30. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
31. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment
32. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling
33. T-cell-mediated lysis of endothelial cells in acute coronary syndromes
34. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
35. Weight loss reduces C-reactive protein levels in obese postmenopausal women
36. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
37. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women
38. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship?
39. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
40. Joint effects of C-reactive protein and other risk factors on acute coronary events
41. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
42. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
43. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
44. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
45. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy
46. Platelet CD40 ligand (CD40L): Subcellular localization, regulation of expression, and inhibition by clopidogrel
47. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
48. Atherosclerosis: The emerging role of inflammation and the CD40-CD40 ligand system
49. Soluble CD40L and cardiovascular risk in women
50. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
51. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein
52. The MRC/BHF Heart Protection Study: Preliminary results
53. Long-term effects of pravastatin on plasma concentration of C-reactive protein
54. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
55. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
56. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
57. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
58. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
59. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation
60. Blood-pressure reduction and cardiovascular risk in HOPE study
61. Blood pressure and inflammation in apparently healthy men
62. Effect of beta-blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris
63. ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis
64. Angiotensin converting enzyme inhibitor restrains inflammation-induced vascular injury in mice
65. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
66. Associations between change in C-reactive protein and serum lipids during statin treatment
67. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate Versus Atorvastatin Trial-FAT)
68. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia
69. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
70. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes
71. Effects of rosiglitazone treatment on levels of C-reactive protein and MMP9 in patients with Type 2 Diabetes
72. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo: A new method of detection by application of a special thermography catheter
73. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation
74. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation
75. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events
76. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban)
77. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
78. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial
79. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention